PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

To develop novel biopharmaceuticals that target the immune system to treat cancer more effectively with fewer side effects.

To become a leading innovator in the development and commercialization of therapeutic biopharmaceuticals for cancer patients.

PDS Biotechnology has been recognized for its innovative approach to cancer research and has received several awards, including a 2016 Fast Company Most Innovative Companies Award, a 2017 Technology & Engineering Emmy Award, a 2017 Prix Galien USA Research Award, and a 2019 Society for Immunotherapy of Cancer Meritorious Achievement Award for improving patient care.